COMMUNIQUÉS West-GlobeNewswire

Coloplast delivers solid full-year result and 8% growth for the sixth quarter running
01/11/2018
Coloplast delivered 8% organic revenue growth in the fourth quarter of the 2017/18 financial year and 8% full-year organic revenue growth as well as a 31% EBIT margin. The company is guiding for ~8% organic revenue [...]
Announcement no. 9/2018 - Full-year Financial Results 2017/18
01/11/2018
2017/18 Announcement of full-year financial results 2017/18 (01 October 2017 - 30 September 2018) Highlights Lars Rasmussen steps down as CEO of Coloplast A/S. The Board of Directors appoints Kristian Villumsen as new [...]
Lars Rasmussen resigns his position as CEO of Coloplast A/S. The board has appointed current Executive Vice President for Coloplast Chronic Care, Kristian Villumsen, as new CEO of the company.
01/11/2018
After 30 years in Coloplast, 17 of them in Executive Management and 10 years as CEO, Lars Rasmussen has decided to resign his position as CEO of Coloplast A/S as of December 4 th, 2018. Succeeding Lars, who during his [...]
Announcement no. 8/2018 - Lars Rasmussen steps down as CEO of Coloplast A/S
01/11/2018
Announcement No. 08/2018 1 November 2018 Lars Rasmussen steps down as CEO of Coloplast A/S. The Board of Directors appoints Kristian Villumsen as new CEO of Coloplast A/S. Coloplast A/S announces today that after 30 [...]
Nephros to Report Third Quarter 2018 Financial Results on November 8th, 2018
01/11/2018
SOUTH ORANGE, NJ, Nov. 01, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (OTCQB: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, [...]
Arrayit Corporation and TeleChem International Inc Celebrate 25 Years in Business
01/11/2018
Sunnyvale, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, announces that management and staff are commemorating its 25-year business anniversary. [...]
AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases
01/11/2018
Key Opinion Leaders to discuss emerging concepts in the development of therapies for Alzheimer's Disease and other neurodegenerative diseases Meeting scheduled for November 5, 2018, from 12:00pm - 2:00pm ET AC Immune's [...]
Amarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations
01/11/2018
Activities Underway to Support Planned Commercial Expansion Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc ( [...]
OV - Clinical up-date
01/11/2018
Clinical up-date : Oncology Venture aims for approval of LiPlaCis ® based on pivotal study in less than 200 patients Hoersholm, Denmark and Cambridge, MA, US, November 1, 2018 - Oncology Venture A/S ("OV" or "the [...]
Notice to convene the Annual General Meeting 2018
01/11/2018
Company Announcement No. 19 / 2018 November 1, 2018 The Annual General Meeting of Chr. Hansen Holding A/S will be hold on Thursday November 29, 2018 at 4:00 p.m. CET at the Company’s premises, Bøge Allé 10-12, 270 [...]
Orion Research Foundation grants million euros for research in 2019
01/11/2018
Orion Research Foundation sr Press release 1 November 2018 at 9.30 a.m. Orion Research Foundation grants million euros for research in 2019 Orion Research Foundation sr is distributing EUR 1,004,800 in research grants [...]
Henrik Juuel Joins Bavarian Nordic as Chief Financial Officer
01/11/2018
COPENHAGEN, Denmark, November 1, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that Henrik Juuel today has taken up the position as Executive Vice President and Chief Financial Officer (CFO) of Bavarian [...]
Rule 2.9 Announcement
01/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 1 November 2018 [...]
Form 8 (DD) - Flemming Ornskov
01/11/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Novo Nordisk's operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018
01/11/2018
Adjusting for severance costs related to lay-offs in the third quarter of 2018, operating profit increased by 4% in local currencies. Sales decreased by 2% in Danish kroner and increased by 4% in local currencies to DKK [...]
Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases
01/11/2018
Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases Candidate molecules have the potential to treat multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's [...]
Sanofi et Denali Therapeutics vont développer des médicaments pour le traitement de maladies neurologiques et inflammatoires
01/11/2018
Sanofi et Denali Therapeutics vont développer des médicaments pour le traitement de maladies neurologiques et inflammatoires Des molécules candidates pour le traitement potentiel de la sclérose en plaques (SEP), de la [...]
Biocartis Group NV: Eight Idylla(TM) Performance Studies to be Presented at the Association for Molecular Pathology Conference in the US
01/11/2018
PRESS RELEASE : 1 November 2018, 07:00 CEST/00:00 CDT Eight Idylla(TM) Performance Studies to be Presented at the 'Association for Molecular Pathology' Conference in the US Mechelen, Belgium, 1 November 2018 - Biocartis [...]
Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
01/11/2018
Candidate RIPK1 inhibitor molecules have the potential to treat Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory diseases Denali to receive $125 million [...]

Pages